首页 > 最新文献

Journal of insurance medicine (New York, N.Y.)最新文献

英文 中文
Checking the Pulse: A Global Survey on the Evolving Roles of the Insurance Medical Director. 检查脉搏:关于保险医疗主管角色演变的全球调查。
Q3 Medicine Pub Date : 2022-07-01 DOI: 10.17849/insm-49-3-1-11.1
Sheetal S Salgaonkar, Leigh Allen, Daniel Zimmerman

Background and objective: -The traditional role of the insurance medical director is evolving. RGA surveyed insurance medical directors to provide an overview of their roles, skill sets, future trends, and their increasing and changing contributions to the insurance industry in recent years and throughout the current pandemic.

Method: -RGA conducted a first-of-a-kind global survey of medical directors in the insurance industry. The online survey took place from April to June 2021 and had seven key sections: medical experience and qualifications, roles and responsibilities, underwriting and claims capabilities, adapting to change, disease and product trends in insurance, challenges, and future opportunities. Globally, 124 insurance medical directors from 84 companies participated in the survey.

Results: -Respondents are an experienced group of medical directors, with 88% active in the medical profession for 10 years or more. Eighty-seven respondents (70%) dedicate the majority of their time to providing technical medical expertise. Forty-eight percent of medical directors were involved in medical issue briefings prior to the pandemic, and that number increased to 63% during the pandemic. Three of every five respondents (60%) reported a shift in underwriting to an emphasis on more competitive decisions, e-underwriting, and data analytics, while for claims practices, 35% reported a shift to more decisions being challenged and increasing complexity of claims and products. In addition, 31% of insurance medical directors are involved in product development on a regular basis. Only 50% of respondents reported a high or moderate level of investment from employers for training and development with their companies. Forty-three percent of survey respondents are interested in a change of role, especially those with less than 15 years of experience in the insurance industry. Medical directors see data and analytics (50%) as the largest area of development for future growth. Eighty-eight percent of participants surveyed believe that the future role of the medical director in the life and health insurance industry is promising.

Conclusion: -The future of the medical director role will require more strategic responsibilities, greater product development expertise, and stronger data and analytics skills to support insurer needs. It will be important for insurance medical directors to engage in conversations with their employers to discuss their current and emerging roles.

背景和目的:-保险医疗主任的传统角色正在演变。RGA对保险公司的医疗主管进行了调查,概述了他们的作用、技能、未来趋势,以及他们近年来和在当前大流行期间对保险业不断增加和不断变化的贡献。方法:rga对保险行业的医疗主管进行了首次全球调查。该在线调查于2021年4月至6月进行,分为七个关键部分:医疗经验和资格、角色和责任、承保和索赔能力、适应变化、保险中的疾病和产品趋势、挑战和未来机遇。来自全球84家保险公司的124名医疗主管参与了此次调查。结果:受访者是一群经验丰富的医疗主任,88%的人在医疗行业活跃了10年或以上。87名受访者(70%)将大部分时间用于提供技术医疗专业知识。在大流行之前,48%的医务主任参与了医疗问题简报,在大流行期间,这一数字增加到63%。五分之三的受访者(60%)表示,承保业务转向强调更具竞争力的决策、电子承保和数据分析,而在索赔实践方面,35%的受访者表示,更多的决策受到挑战,索赔和产品的复杂性也在增加。此外,31%的保险医疗主管定期参与产品开发。只有50%的受访者表示,雇主对其公司的培训和发展进行了高或中等水平的投资。43%的受访者对转变角色感兴趣,尤其是那些在保险行业工作不到15年的人。医疗主管将数据和分析(50%)视为未来增长的最大发展领域。88%的受访者认为,医疗总监在生命和健康保险行业的未来角色是有前途的。结论:-未来的医疗总监角色将需要更多的战略责任,更强的产品开发专业知识,以及更强的数据和分析技能,以支持保险公司的需求。对于保险公司的医疗主管来说,与雇主进行对话,讨论他们目前和未来的角色是很重要的。
{"title":"Checking the Pulse: A Global Survey on the Evolving Roles of the Insurance Medical Director.","authors":"Sheetal S Salgaonkar,&nbsp;Leigh Allen,&nbsp;Daniel Zimmerman","doi":"10.17849/insm-49-3-1-11.1","DOIUrl":"https://doi.org/10.17849/insm-49-3-1-11.1","url":null,"abstract":"<p><strong>Background and objective: </strong>-The traditional role of the insurance medical director is evolving. RGA surveyed insurance medical directors to provide an overview of their roles, skill sets, future trends, and their increasing and changing contributions to the insurance industry in recent years and throughout the current pandemic.</p><p><strong>Method: </strong>-RGA conducted a first-of-a-kind global survey of medical directors in the insurance industry. The online survey took place from April to June 2021 and had seven key sections: medical experience and qualifications, roles and responsibilities, underwriting and claims capabilities, adapting to change, disease and product trends in insurance, challenges, and future opportunities. Globally, 124 insurance medical directors from 84 companies participated in the survey.</p><p><strong>Results: </strong>-Respondents are an experienced group of medical directors, with 88% active in the medical profession for 10 years or more. Eighty-seven respondents (70%) dedicate the majority of their time to providing technical medical expertise. Forty-eight percent of medical directors were involved in medical issue briefings prior to the pandemic, and that number increased to 63% during the pandemic. Three of every five respondents (60%) reported a shift in underwriting to an emphasis on more competitive decisions, e-underwriting, and data analytics, while for claims practices, 35% reported a shift to more decisions being challenged and increasing complexity of claims and products. In addition, 31% of insurance medical directors are involved in product development on a regular basis. Only 50% of respondents reported a high or moderate level of investment from employers for training and development with their companies. Forty-three percent of survey respondents are interested in a change of role, especially those with less than 15 years of experience in the insurance industry. Medical directors see data and analytics (50%) as the largest area of development for future growth. Eighty-eight percent of participants surveyed believe that the future role of the medical director in the life and health insurance industry is promising.</p><p><strong>Conclusion: </strong>-The future of the medical director role will require more strategic responsibilities, greater product development expertise, and stronger data and analytics skills to support insurer needs. It will be important for insurance medical directors to engage in conversations with their employers to discuss their current and emerging roles.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 3","pages":"189-199"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39944740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long COVID - One Year On. 长冠-一年过去了。
Q3 Medicine Pub Date : 2022-05-13 DOI: 10.17849/insm-49-3-1-6.1
Timothy J. Meagher
Long COVID is now a recognized complication of acute COVID-19 infection. As the COVID-19 pandemic moves into its third year, the prevalence of Long COVID continues to increase. Many individuals report symptoms lasting longer than a year, and a subset of this group is unable to work. This article will provide an update on Long COVID, with a particular focus on distinguishing it from other clinical entities. It will review several proposed disease mechanisms and will attempt to anticipate the impact on disability insurance.
长冠状病毒病现已被公认为急性COVID-19感染的并发症。随着2019冠状病毒病大流行进入第三年,长冠状病毒病的流行率继续上升。许多人报告症状持续时间超过一年,其中一部分人无法工作。本文将提供关于Long COVID的最新信息,特别侧重于将其与其他临床实体区分开来。它将审查几种拟议的疾病机制,并将试图预测对残疾保险的影响。
{"title":"Long COVID - One Year On.","authors":"Timothy J. Meagher","doi":"10.17849/insm-49-3-1-6.1","DOIUrl":"https://doi.org/10.17849/insm-49-3-1-6.1","url":null,"abstract":"Long COVID is now a recognized complication of acute COVID-19 infection. As the COVID-19 pandemic moves into its third year, the prevalence of Long COVID continues to increase. Many individuals report symptoms lasting longer than a year, and a subset of this group is unable to work. This article will provide an update on Long COVID, with a particular focus on distinguishing it from other clinical entities. It will review several proposed disease mechanisms and will attempt to anticipate the impact on disability insurance.","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67476463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Projection of Impaired Life Expectancy in Individuals in the United Kingdom Using Mortality Ratios. 使用死亡率预测英国个人预期寿命受损
Q3 Medicine Pub Date : 2022-04-01 DOI: 10.17849/insm-49-02-02
David Bowen Jones, Nicole R Gray, Madeleine Reid, William F Scott

Projections of life expectancy are widely used in medicine, actuarial practice, and in the medicolegal and insurance fields. For individuals considered to have average future survival, nationally-derived life expectancy tables are available, referred to as the Ogden Tables. In the United Kingdom, updated tables (the 8th edition) were published in July 2020. We have calculated impaired projected life expectancies for the United Kingdom based on age and gender, derived from the 8th edition of the Ogden Tables together with various assumed lifelong mortality ratios.

预期寿命预测广泛应用于医学、精算实践、医学法律和保险领域。对于被认为具有平均未来生存率的个人,可以使用国家派生的预期寿命表,即奥格登表。在英国,更新的表格(第8版)于2020年7月发布。我们根据第八版奥格登统计表以及各种假定的终身死亡率,计算了英国按年龄和性别划分的预期寿命受损情况。
{"title":"Projection of Impaired Life Expectancy in Individuals in the United Kingdom Using Mortality Ratios.","authors":"David Bowen Jones,&nbsp;Nicole R Gray,&nbsp;Madeleine Reid,&nbsp;William F Scott","doi":"10.17849/insm-49-02-02","DOIUrl":"https://doi.org/10.17849/insm-49-02-02","url":null,"abstract":"<p><p>Projections of life expectancy are widely used in medicine, actuarial practice, and in the medicolegal and insurance fields. For individuals considered to have average future survival, nationally-derived life expectancy tables are available, referred to as the Ogden Tables. In the United Kingdom, updated tables (the 8th edition) were published in July 2020. We have calculated impaired projected life expectancies for the United Kingdom based on age and gender, derived from the 8th edition of the Ogden Tables together with various assumed lifelong mortality ratios.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 2","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39268753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer of the Liver, Intrahepatic Bile Ducts, Gallbladder, Exocrine and Neuroendocrine Pancreas: 20-Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes A Systematic Review of 367,420 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4). 肝癌、肝内胆管癌、胆囊癌、外分泌癌和神经内分泌胰腺癌:按年龄、性别、种族、分期、分级、队列入组时间、病程和选定的ICD-O-3肿瘤表型进行的20年生存率和死亡率比较分析。
Q3 Medicine Pub Date : 2022-04-01 DOI: 10.17849/insm-49-2-1-36.1
Anthony F Milano

This article summarizes the results of a review of adult invasive primary cancers of the liver, intrahepatic bile ducts, gallbladder, exocrine and endocrine pancreas, as recorded in the SEER Program of the National Cancer Institute for diagnosis years 1973-2014 (SEER Stat 8.3.4).

本文总结了1973-2014年美国国家癌症研究所(National Cancer Institute) SEER项目诊断记录的成人侵袭性原发性肝癌、肝内胆管癌、胆囊癌、外分泌癌和内分泌胰腺癌(SEER Stat 8.3.4)的研究结果。
{"title":"Cancer of the Liver, Intrahepatic Bile Ducts, Gallbladder, Exocrine and Neuroendocrine Pancreas: 20-Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes A Systematic Review of 367,420 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).","authors":"Anthony F Milano","doi":"10.17849/insm-49-2-1-36.1","DOIUrl":"https://doi.org/10.17849/insm-49-2-1-36.1","url":null,"abstract":"<p><p>This article summarizes the results of a review of adult invasive primary cancers of the liver, intrahepatic bile ducts, gallbladder, exocrine and endocrine pancreas, as recorded in the SEER Program of the National Cancer Institute for diagnosis years 1973-2014 (SEER Stat 8.3.4).</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 2","pages":"60-96"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39699154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JIM Reading List. JIM阅读列表。
Q3 Medicine Pub Date : 2022-04-01 DOI: 10.17849/insm-49-2-119-125.1
{"title":"JIM Reading List.","authors":"","doi":"10.17849/insm-49-2-119-125.1","DOIUrl":"https://doi.org/10.17849/insm-49-2-119-125.1","url":null,"abstract":"","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 2 1","pages":"119-125"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45103506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Projection of Impaired Life Expectancy for Individuals in the United Kingdom Using Estimated Excess Death Rates. 利用估计的超额死亡率预测英国个人预期寿命受损。
Q3 Medicine Pub Date : 2022-04-01 DOI: 10.17849/insm-49-02-01
David Bowen Jones, Nicole R Gray, Madeleine Reid, William F Scott

We have recently constructed tables of the estimated life expectancies of impaired lives on the basis of mortality ratios and the cohort life expectancy tables given in the 8th edition of the Ogden Tables, which are derived from the ONS 2018-based population projections for the United Kingdom.1,2 The life expectancy of impaired lives may also be estimated using excess death rates. In this paper, we give tables of life expectancies for impaired lives using a range of excess death rates for males and females from age 0 to age 100. As both mortality ratios and excess death rates are widely used in medical and legal settings, it is hoped that these additional tables of life expectancies will be of practical value.

我们最近根据死亡率和《奥格登表》第8版中给出的队列预期寿命表构建了受损生命的预期寿命表,这些预期寿命表来自于英国国家统计局基于2018年的人口预测。在本文中,我们使用从0岁到100岁的男性和女性的超额死亡率范围给出了受损生命的预期寿命表。由于死亡率和超额死亡率在医疗和法律环境中被广泛使用,希望这些额外的预期寿命表具有实用价值。
{"title":"Projection of Impaired Life Expectancy for Individuals in the United Kingdom Using Estimated Excess Death Rates.","authors":"David Bowen Jones,&nbsp;Nicole R Gray,&nbsp;Madeleine Reid,&nbsp;William F Scott","doi":"10.17849/insm-49-02-01","DOIUrl":"https://doi.org/10.17849/insm-49-02-01","url":null,"abstract":"<p><p>We have recently constructed tables of the estimated life expectancies of impaired lives on the basis of mortality ratios and the cohort life expectancy tables given in the 8th edition of the Ogden Tables, which are derived from the ONS 2018-based population projections for the United Kingdom.1,2 The life expectancy of impaired lives may also be estimated using excess death rates. In this paper, we give tables of life expectancies for impaired lives using a range of excess death rates for males and females from age 0 to age 100. As both mortality ratios and excess death rates are widely used in medical and legal settings, it is hoped that these additional tables of life expectancies will be of practical value.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 2","pages":"97-104"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39276418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low Serum Creatinine as a Marker for Undisclosed Alcohol Abuse. 低血清肌酐作为未公开的酒精滥用的标志。
Q3 Medicine Pub Date : 2022-04-01 DOI: 10.17849/insm-49-2-1-3.1
Vera Dolan

Detecting undisclosed alcohol abuse in life insurance applicants has always been a challenge to life underwriters and medical directors. This case report describes a 38-year-old woman with classic signs, symptoms, behavior and biochemical markers of undisclosed alcohol abuse. Review of 10 years of medical records revealed chronic abnormally low serum creatinine results associated with abnormally elevated liver function tests, and repeated denials to attending physicians of ever consuming alcohol. Kidney function throughout the 10-year history was not impaired. Low serum creatinine may be a good marker for detecting undisclosed alcohol abuse, but only when there is no kidney injury, dysfunction or impairment obscuring it.

对人寿保险公司和医疗主管来说,在投保人身上发现未披露的酗酒行为一直是一个挑战。本病例报告描述了一名38岁的女性,她具有未公开的酒精滥用的典型体征、症状、行为和生化指标。对10年医疗记录的回顾显示,慢性异常低血清肌酐结果与肝功能检查异常升高有关,并反复向主治医生否认曾经饮酒。肾脏功能在整个10年的历史中没有受损。低血清肌酐可能是检测未公开的酒精滥用的一个很好的标志,但只有当没有肾脏损伤、功能障碍或损害掩盖它。
{"title":"Low Serum Creatinine as a Marker for Undisclosed Alcohol Abuse.","authors":"Vera Dolan","doi":"10.17849/insm-49-2-1-3.1","DOIUrl":"https://doi.org/10.17849/insm-49-2-1-3.1","url":null,"abstract":"<p><p>Detecting undisclosed alcohol abuse in life insurance applicants has always been a challenge to life underwriters and medical directors. This case report describes a 38-year-old woman with classic signs, symptoms, behavior and biochemical markers of undisclosed alcohol abuse. Review of 10 years of medical records revealed chronic abnormally low serum creatinine results associated with abnormally elevated liver function tests, and repeated denials to attending physicians of ever consuming alcohol. Kidney function throughout the 10-year history was not impaired. Low serum creatinine may be a good marker for detecting undisclosed alcohol abuse, but only when there is no kidney injury, dysfunction or impairment obscuring it.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 2","pages":"114-116"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39654038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insurance and Improving Its Strategic Purchase in Iran. 保险与改进在伊朗的战略采购。
Q3 Medicine Pub Date : 2022-03-04 DOI: 10.17849/insm-49-2-1-2.1
Mahdieh Motie, R. Dehnavieh, Khalil Kalavani
As in most countries, patients, health care providers, and insurance organizations are key components of the health care system in Iran. High rates of growth and development in today's financial markets, have made the insurance industry with its unique calculations and models, a prominent player in this specialized economic sector.
与大多数国家一样,患者、卫生保健提供者和保险组织是伊朗卫生保健系统的关键组成部分。当今金融市场的高速增长和发展,使保险业以其独特的计算和模型,在这个专业的经济部门中扮演着重要的角色。
{"title":"Insurance and Improving Its Strategic Purchase in Iran.","authors":"Mahdieh Motie, R. Dehnavieh, Khalil Kalavani","doi":"10.17849/insm-49-2-1-2.1","DOIUrl":"https://doi.org/10.17849/insm-49-2-1-2.1","url":null,"abstract":"As in most countries, patients, health care providers, and insurance organizations are key components of the health care system in Iran. High rates of growth and development in today's financial markets, have made the insurance industry with its unique calculations and models, a prominent player in this specialized economic sector.","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46736314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Special Needs Insurance: More Stability for a Growing Family's Budget. 特殊需要保险:增加家庭预算的稳定性。
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.17849/insm-49-s1-1-31.1
David Morel

Objective.—: To propose an insurance product called special needs insurance. The insurance will pay parents a lump sum up to $100,000 if they have a child that is born with or develops a special needs condition such as Down syndrome, cerebral palsy or autism.

Background.—: Raising a child is expensive; raising a child with a special need can be hundreds of thousands of dollars more expensive. These additional costs include direct costs that are not covered by health insurance and indirect costs such as the loss of earnings when a working parent must tend to a special needs child.

Method.—: We analyze a gamut of birth and early childhood disabilities, both physical and cognitive, from the medico-actuarial perspective. We describe each condition using relevant medical literature and calculate prevalence rates from epidemiological studies (appendix A1-A15). After accounting for multiple births, we develop a final premium.

Results.—: We find that physical impairments are sufficiently well understood to guarantee a fixed payout, whereas cognitive impairments such as autism are less understood, and so for these we propose a cognitive fund that does not guarantee a fixed payout. We find that an average single premium of $4,600 allows the insurer to profitably pay out the proposed benefits.

Conclusions.—: Raising a special needs child can put a significant strain on the affected family's budget. We propose an insurance product that provides relief through a large lump sum payout. Although no new insurance product can be guaranteed success, our analysis of this product gives an interested insurer reasonable justification to take on this new risk.

目标。-:提出一种叫做特殊需要保险的保险产品。如果孩子出生时患有唐氏综合症、脑瘫或自闭症等特殊疾病,该保险将一次性向父母支付高达10万美元的赔偿金。抚养孩子是很昂贵的;抚养一个有特殊需要的孩子可能要花费数十万美元。这些额外费用包括不包括在健康保险范围内的直接费用和间接费用,如工作的父母必须照顾有特殊需要的孩子时的收入损失。-:我们从医学精算的角度分析了一系列出生和幼儿残疾,包括身体残疾和认知残疾。我们使用相关的医学文献描述每种情况,并从流行病学研究中计算患病率(附录A1-A15)。在考虑了多胞胎之后,我们得出了最终的保费。-:我们发现身体损伤已经得到了充分的了解,可以保证固定的支出,而像自闭症这样的认知障碍则不太了解,因此我们提出了一个认知基金,但不能保证固定的支出。我们发现,单次平均保费为4,600美元,保险公司就能以盈利的方式支付拟议的福利。抚养一个有特殊需要的孩子会给受影响家庭的预算带来很大的压力。我们建议一种保险产品,通过大额一次性支付来提供救济。虽然没有新的保险产品可以保证成功,但我们对该产品的分析为感兴趣的保险公司提供了承担这种新风险的合理理由。
{"title":"Special Needs Insurance: More Stability for a Growing Family's Budget.","authors":"David Morel","doi":"10.17849/insm-49-s1-1-31.1","DOIUrl":"https://doi.org/10.17849/insm-49-s1-1-31.1","url":null,"abstract":"<p><strong>Objective.—: </strong>To propose an insurance product called special needs insurance. The insurance will pay parents a lump sum up to $100,000 if they have a child that is born with or develops a special needs condition such as Down syndrome, cerebral palsy or autism.</p><p><strong>Background.—: </strong>Raising a child is expensive; raising a child with a special need can be hundreds of thousands of dollars more expensive. These additional costs include direct costs that are not covered by health insurance and indirect costs such as the loss of earnings when a working parent must tend to a special needs child.</p><p><strong>Method.—: </strong>We analyze a gamut of birth and early childhood disabilities, both physical and cognitive, from the medico-actuarial perspective. We describe each condition using relevant medical literature and calculate prevalence rates from epidemiological studies (appendix A1-A15). After accounting for multiple births, we develop a final premium.</p><p><strong>Results.—: </strong>We find that physical impairments are sufficiently well understood to guarantee a fixed payout, whereas cognitive impairments such as autism are less understood, and so for these we propose a cognitive fund that does not guarantee a fixed payout. We find that an average single premium of $4,600 allows the insurer to profitably pay out the proposed benefits.</p><p><strong>Conclusions.—: </strong>Raising a special needs child can put a significant strain on the affected family's budget. We propose an insurance product that provides relief through a large lump sum payout. Although no new insurance product can be guaranteed success, our analysis of this product gives an interested insurer reasonable justification to take on this new risk.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 s1","pages":"1-31"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39632319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19 and Mental Health: Should We Expect an Increase in Disability? COVID-19与心理健康:我们应该期待残疾人数增加吗?
Q3 Medicine Pub Date : 2021-03-30 DOI: 10.17849/insm-49-1-1-8.1
Timothy Meagher

Disability due to mental health disorders has been increasing in many countries over the past years. The COVID-19 pandemic may worsen this trend because of 3 different, and at times overlapping, pathways. This article describes each pathway, and by drawing on the experience of previous coronavirus epidemics and recent recessions, attempts to estimate the likelihood that claims due to mental health disorders will increase.

过去几年来,许多国家因精神健康障碍造成的残疾一直在增加。COVID-19大流行可能会加剧这一趋势,因为有三种不同的、有时是重叠的途径。本文描述了每一种途径,并通过借鉴以前的冠状病毒流行和最近的经济衰退的经验,试图估计精神健康障碍导致的索赔增加的可能性。
{"title":"COVID-19 and Mental Health: Should We Expect an Increase in Disability?","authors":"Timothy Meagher","doi":"10.17849/insm-49-1-1-8.1","DOIUrl":"https://doi.org/10.17849/insm-49-1-1-8.1","url":null,"abstract":"<p><p>Disability due to mental health disorders has been increasing in many countries over the past years. The COVID-19 pandemic may worsen this trend because of 3 different, and at times overlapping, pathways. This article describes each pathway, and by drawing on the experience of previous coronavirus epidemics and recent recessions, attempts to estimate the likelihood that claims due to mental health disorders will increase.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"49 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25530746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of insurance medicine (New York, N.Y.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1